ReviewNanomedicine (London, England)2025
Biological properties of ceragenin-coated metal nanoparticles - future challenges and perspectives in clinical practice.
Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Considering the priority of searching for new therapeutic strategies related to increasing microbial resistance and complex needs of oncological treatment, the potential of ceragenin-coated metal nanoparticles (primarily in the form of core-shell nanosystems) as tools for developing new treatment methods was discussed. In particular, the complex mechanisms of action of the ceragenin-containing nanosystems were described, and the presented actions were compared with the native efficacy of ceragenins. The methods for their synthesis and characterization, taking into account features such as size, shape, surface charge, and colloidal stability, were also presented. The synergy of this combination is a potentially effective alternative for combating multidrug-resistant strains of bacteria, as well as fungi. This is also crucial when counteracting the biofilms forming on the surfaces of implants, catheters, or endotracheal tubes. When applying for cancer therapies, the employment of modified ceragenin nanosystems as targeted drug delivery systems may help achieve higher drug concentrations in the tumor environment as well as lower systemic toxicity compared to current therapeutic methods. The collected data justify the need for further studies to fully assess the safety and therapeutic efficacy of ceragenin-containing nanosystems, which will certainly translate into the development of innovative therapeutic methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.